Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
暂无分享,去创建一个
M. Beksac | M. Dimopoulos | T. Facon | L. Benboubker | C. Couturier | H. Roddie | M. Mazier | R. Angermund | Nathalie Allietta | E. Broer | M. Beksaç